# OrigAMI-4 (NCT06385080)

> A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06385080
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Squamous Cell Carcinoma of Head and Neck
- Interventions: Amivantamab; Pembrolizumab; Paclitaxel; Carboplatin
- Enrollment: 287
- Primary outcome: Cohorts 1, 2, 3B, 4 and 5: Objective Response Rate
- Primary outcome: Cohort 3A: Number of Participants With Dose-limiting Toxicities (DLT)
- Primary outcome: Cohort 3A: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Severity
- Primary outcome: Cohort 6: Major Pathologic Response (MPR)

## Commentary we found

- YouTube: 16
- Podcasts: 7
- X threads: 6
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=origami-4-nct06385080

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06385080", "email": "<work email>"}; the inbox owner confirms by the emailed link.